Archives

The ABCD of Off-Label Medications for Weight Management-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

1.     Discuss the main principles of management of adiposity-based chronic disease (ABCD)
2.     Identify the efficacy of commonly prescribed medications that may be used off-label for weight reduction
3.     List major safety considerations for medications prescribed off-label for weight reduction

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-038-H01-P

Session Code

23RW38-CBA96

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-038-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Khanh Dang, PharmD, CDCES, FNAP
Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Dang has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Post Test

The ABCD of Off-Label Medications for Weight Management
Post Test
1. When working with a patient to manage ABCD, what is the first goal?

A. prevent weight regain
B. stop further weight gain
C. achieve weight reduction

2. Which of the following is the correct order of weight reduction efficacy (highest to lowest)?

A. tirzepatide > semaglutide > phentermine
B. semaglutide > SGLT2 inhibitors > phentermine
C. metformin = semaglutide > topiramate

3. What did the SELECT RCT report about patients 45 years and older with ABCD and existing cardiovascular disease who did not have diabetes?

A. The placebo-subtracted weight reduction for weekly semaglutide 2.4 mg was 15% of baseline body weight.
B. Subcutaneous semaglutide 2.4 mg once weekly reduced major adverse cardiovascular events in ABCD.
C. Subcutaneous semaglutide 2.4 mg once weekly significantly reduced weight but did not prevent cardiovascular events.

4. What is the most common adverse reaction for GLP-1 receptor agonist-based medications?

A. nausea and other gastrointestinal adverse effects
B. hypoglycemia
C. sleep disturbance

5. With which drug class can tirzepatide interact ?

A. beta blockers
B. ACE inhibitors
C. oral hormonal contraceptives

Handouts

VIDEO

TOP 10 Cardiovascular Drugs Used Off Label!!!-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

  • Identify how an FDA approved and off label indication differ and the implications of that differential designation
  • Identify which 10 FDA approved cardiovascular drugs have the most promising off label uses for treating other cardiac or noncardiac disorders
  • Describe the mechanisms of action for the purported off label uses of these drugs
  • Identify which national guidelines or consensus statements recommend the off-label use of drugs

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-039-H01-P

Session Code

23RW39-TXJ88

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-039-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

C. Michael White, PharmD, FCCP, FCP
BOT Distinguished Professor and Chair of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, CT              

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. White has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Post Test “TOP 10 Cardiovascular Drugs Used Off Label!!!”

1. Which of the following drugs has been used to enhance the chances of delivering a baby in patients with Factor 5 Leiden and what is the mechanism of benefit?
a) Thiazide diuretics; reduced placental calcium that stops crystalline umbilical cord blockage
b) LMWH; preventing placental thrombosis in patients who are hypercoagulable
c) Disopyramide – decreasing the inotropic effect in hypertrophic cardiomyopathy that leads to placental detachment

2. Which of the following drugs is effective for treating anal fissures and what is the mechanism of action?
a) IV iron; iron deficiency anemia promotes fissure formation so treating it reverses fissure
b) Amiodarone; overactive potassium channels in the anus lead to apoptosis of anal mucosal cells
c) CCBs; Blood vessel dilation enhancing blood flow to targeted areas in the body

3. Which of the following drugs is properly linked to the off-label indication it is commonly used for?
a) Beta-blockers – Raynaud’s phenomenon
b) Prazosin – Nightmares in PTSD patients
c) Clonidine – Stage fright

4. Which of the following drugs is used off label for the treatment of abnormal face and body hair growth in patients and what is the mechanism of action?
a) Spironolactone – blocking the effects of testosterone in several ways
b) Beta-blockers – blocking epinephrine induced follicular stimulation
c) Clonidine – central outflow of norepinephrine causes abnormal hair growth

5. Sally Sue has had atrial fibrillation for several months. Her cardiologist has prescribed several therapies that have been ineffective, and one that is on the drug shortage list and hard to find. Which of the following might the cardiologist use off-label according to the AHA/ACC Guideline?

a) Calcium channel blockers
b) Prazocin
c) Amiodarone

Handouts

VIDEO

Antipsychotic Utilization in a Pediatric Population-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

1. Describe current practice guidelines regarding the use of antipsychotic medications in a pediatric population.
2.  Outline adverse effects associated with the use of antipsychotic medication in a pediatric population.
3.  Discuss when to initiate an antipsychotic medication in a pediatric patient.

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-043-H01-P

Session Code

23RW43-XYW84

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-043-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Megan J. Ehret PharmD, MS, BCPP
Professor, Co-Director of Mental Health Program
University of Maryland School of Pharmacy
Baltimore, MD

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Ehret is a consultant with Saladex Biomedical

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Post Test

Antipsychotic Utilization in a Pediatric Population

Megan Ehret, PharmD

 
1. Which medication is a first-line treatment option for a 14-year-old patient with newly diagnosed schizophrenia?
a. Divalproex Sodium
b. Haloperidol
C. Risperidone

2. Which medication is a first-line treatment option for a 16-year-old patient with bipolar disorder, most recent episode depressed?
A. Aripiprazole
B. Divalproex Sodium
C. Lurasidone

3. Which medication can cause the most substantial weight gain?
A. Cariprazine
B. Lumateperone
C. Olanzapine

4. Which rating scale should be used to screen patients for tardive dyskinesia?

A. Extrapyramidal Symptom Rating Scale
B. Barnes Akathisia Rating Scale
C. Abnormal Involuntary Movement Scale

5. In which disease state would it be appropriate to initiate an antipsychotic medication in a pediatric patient?
A. Autism
B. Conduct Disorder
C. Intellectual Disability

Handouts

VIDEO

Immunization: It is Now Time to Make it Unclear: Reconciling Differences between Public Health Vaccine Recommendations and FDA Product Labeling-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

1. Compare and contrast the roles & activities of the Center for Biologics Evaluations and Research (CBER), US Food & Drug Administration (FDA), Centers for Disease Control & Prevention (CDC), and the Advisory Committee on Immunization Practices (ACIP) during the development and clinical use of vaccines in the United States.
2. Describe one specific example where the routine clinical use of a vaccine may differ from FDA-approved product prescribing information due to the following:

(a) costs, (b) disease epidemiology, (c) public acceptance, (d) vaccine supplies.

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-042-H06-P

Session Code

23RW42-KXV39

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-042-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Jeffery Aeschlimann, PharmD
Associate Clinical Professor-Infectious Disease Specialty
University of Connecticut School of Pharmacy
Storrs, CT  

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Aeschlimann consults with F2G, Inc. but there is no crossover in the topics, so all issues have been mitigated.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Post Test

 

    Immunizations (Aeschlimann) – Post-Test Questions

     

     

    1. If asked, which of the following activities would the Food and Drug Administration decline to do and send to another agency?

     

    1. Verify appropriate vaccine manufacturing processes
    2. Approve advertising for vaccine products Reporting System (VAERS)
    3. Determine the strategy for public use of vaccines in the U.S.

     

     

    2.) Which of the following items would you expect to always/very-commonly see in the FDA-Approved product labeling for a vaccine product?

     

    1. Instructions for preparation of the product and route of administration
    2. Comparative effectiveness data for people taking chronic steroid therapy
    3. Recommendations for use of lower doses in case of product shortages

     

     

    3.) Which of the following is a correct example of a vaccination situation for which ACIP has issued “Shared Clinical Decision-making” (SCDM) guidance?

     

    1. Intranasal influenza vaccine administration in immunocompromised persons
    2. Respiratory syncytial virus vaccination for adults aged 60 years and older
    3. Human papillomavirus vaccination for persons aged 16-21 years

     

     

    4.) Which entity ultimately approves the content for FDA vaccine product labeling?

     

    1. The Vaccines and Related Biological Products Advisory Committee
    2. The Center for Biologic Evaluation & Research
    3. The Center for Drug Evaluation and Research

     

     

    5.) Which of the following people would be allowed to sit in the CDC’s Advisory Committee on Immunization Practices (ACIP)?

     

    1. A member of a vaccine manufacturer’s current Board of Directors
    2. A college professor whose expertise is mechanical engineering
    3. A practicing physician who is an expert in virology and vaccine safety

     

     

    6.) What does ACIP recommend after healthcare providers receive a full series of hepatitis B immunizations?

     

    1. Serologic testing for all healthcare providers at high risk for occupational percutaneous or mucosal exposure to blood or body fluids.
    2. Serologic testing for immunocomproised healthcare providers at high risk for occupational percutaneous of any type.
    3. Molecular testing for all healthcare providers at high risk for occupational percutaneous or mucosal exposure to blood or body fluids.

    VIDEO

    Time to Learn about New Cardiac Drugs-RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    • Select the appropriate first and adjunctive therapies for LDL lowering in patients with differing risks according to guideline recommendations
    • Compare and contrast the mechanism of action and potential utility of the new LDL lowering drugs bempedoic acid and inclisirin versus traditional options
    • Describe hypertrophic cardiomyopathy and its risks
    • Identify the mechanism of action and potential utility of mavacamten versus agents currently recommended in guidelines

    Release and Expiration Dates

    Released:  December 16, 2022
    Expires:  December 16, 2025

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-22-056-H01-P

    Session Code

    22RW56-TXJ88

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-056-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    C. Michael White, PharmD, FCCP, FCP
    BOT Distinguished Professor and Chair of Pharmacy Practice
    University of Connecticut School of Pharmacy
    Storrs, CT              

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. White has no relationships with ineligible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test

    Mary Maple is an 80-year old with angina pectoris, what intensity of statin therapy should she receive and how much should her LDL be reduced?
    a) Moderate intensity, 30%
    b) High intensity, 50%
    c) Low intensity, 20%

    Mary Maple is an 55-year old with angina pectoris, what intensity of statin therapy should she receive and how much should her LDL be reduced?
    a) Moderate intensity, 30%
    b) High intensity, 50%
    c) Low intensity, 20%

    According to the CTT relationship, whether the intensity of statin was increased or adjunctive therapy with ezetimibe or evolocumab was used, the relationship between LDL lowering and cardiovascular event reduction had the same relationship
    a) True
    b) False

    Does the CTT relationship apply to inclisirin and bempedoic acid or just to statins, ezetimibe, and PCSK9 inhibitors?
    a) Yes
    b) Unknown
    c) No

    Which of the following describes the mechanism of action correctly?
    a) Inclisiran inhibits the formation of PCSK9 by inserting small interfering RNA into the cell
    b) Bempedoic acid blocks the binding of PCSK9 to the LDL receptor
    c) Both of the mechanisms are described correctly

    Which of the new cholesterol reducing drugs can cause tendon rupture and increased uric acid?
    a. Inclisiran
    b. Bempedoic acid
    c. Both agents

    Which of the following agents can be given every six months once steady state concentrations are achieved?
    a. Inclisiran
    b. Bempedoic acid
    c. Both agents

    Hypertrophic cardiomyopathy can lead to what adverse events?
    a. Atrial and ventricular arrhythmias
    b. Stroke
    c. Both of these issues

    Mavacamten might be able to replace which of the following HCM treatments?
    a. Beta-blockers of Non-DHP CCBs
    b. ICDs or anticoagulants
    c. Disopyramide or septal reduction therapies

    Mavacamten should not be used if the left ventricular ejection fraction goes below what value?
    a. 20%
    b. 30%
    c. 40%
    d. 50%

    Handouts

    VIDEO

    Law: Tic-Toc, Turn Back the Clock: Pharmacy in the Post-Roe v. Wade Climate-RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    1.       Review the original Roe v. Wade ruling and its impact on healthcare in the United States
    2.       Discuss Dobbs v. Jackson Women’s Health Organization and its impact on Roe v. Wade
    3.       Identify the implications of these Supreme Court rulings on pharmacy practice

    Release and Expiration Dates

    Released:  December 16, 2022
    Expires:  December 16, 2025

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-22-057-H03-P

    Session Code

    22RW57-JXT85

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-057-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Kelsey Giara, PharmD
    Freelance Medical Writer
    Pelham, NH

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Kelsey Giara has no relationships with ineligible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test

    Pharmacist Post-test

    Learning Objectives
    After completing this continuing education activity, pharmacists will be able to
    • REVIEW the original Roe v. Wade ruling and how it impacted healthcare in the United States
    • DISCUSS Dobbs v. Jackson Women’s Health Organization and its impact on Roe v. Wade
    • IDENTIFY the implications of these Supreme Court rulings on pharmacy practice

    1. What did the original Roe v. Wade ruling do?
    A. Made abortion legal in the U.S. at any gestational age for any reason
    B. Left it up to individual states in the U.S. to regulate abortion at any gestational age
    C. Made abortion legal in the U.S. through the first trimester of pregnancy

    2. What did the Planned Parenthood of Southeastern Pennsylvania v. Casey ruling do?
    A. Overturned Roe v. Wade and made abortion illegal across the U.S.
    B. Provided states the ability to pass more restrictive laws regarding abortion
    C. Laid the groundwork for Dobbs v. Jackson Women’s Health Organization

    3. What did the Dobbs v. Jackson Women’s Health Organization ruling do?
    A. Made abortion illegal in the U.S. at any gestational age for any reason
    B. Left it up to individual states in the U.S. to regulate abortion at any gestational age
    C. Made abortion illegal in the U.S. after the first trimester of pregnancy

    4. Which of the following was the first successful 6-week abortion ban after the Roe v. Wade ruling?
    A. Gestational Age Act
    B. Partial-Birth Abortion Ban
    C. Heartbeat Act

    5. Which of the following states would be MOST likely to enforce abortion bans through criminal penalties?
    A. Tennessee
    B. New Mexico
    C. Florida

    6. Which of the following is TRUE about EMTALA?
    A. It effectively supersedes state law regarding abortion
    B. It states that providers must abort ectopic pregnancies
    C. It is not enforceable in the case of abortion care

    7. Which of the following is TRUE about dispensing intramuscular methotrexate following the overturn of Roe v. Wade?
    A. Pharmacists should use clinical judgment to practice corresponding responsibility and follow state laws
    B. It is illegal to dispense to a woman of childbearing age unless they have documented psoriatic arthritis
    C. Refusing to fill for any reason is illegal, and pharmacists will face fines and imprisonment for discrimination

    8. Which of the following is the BEST way to prevent discrimination or perceived discrimination?
    A. Ask all women of childbearing age about pregnancy status when they fill teratogenic medications
    B. Decline to fill all prescriptions for abortifacient medications for women of childbearing age
    C. Ask individuals about their religious beliefs before offering them employment

    9. Which of the following is TRUE about federal preemption?
    A. It requires physicians to use telehealth to prescribe medication abortion drugs if patients request
    B. It supersedes the FDA to prohibit providers from prescribing opioids to women of childbearing age
    C. The Women’s Health Protection Act of 2021 may provide federal preemption regarding abortion services

    10. A woman presents to the emergency department at your hospital experiencing complications related to a miscarriage during the ninth week of pregnancy. You work in a state where a 6-week abortion ban is in effect, and a provider suspects the individual of having taken medication to end their pregnancy. A coworker insists on reporting this information to authorities because she does not want to be liable for withholding the information from law enforcement. The law does not require the hospital to report individuals to law enforcement for intentionally ending a pregnancy, but your coworker states that the HIPAA Privacy Rule allows this kind of disclosure. What should you do?
    A. Assure your coworker that reporting this patient to law enforcement is an unlawful disclosure of PHI
    B. Let your coworker report this information to law enforcement and then report your coworker for PHI disclosure
    C. Report this patient to law enforcement so that you are not held liable if she is later charged with unlawful abortion

    Handouts

    VIDEO

    LAW: Legal Perspectives on New and Evolving Issues in Pharmacy-RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    1. Describe recent industry trends and regulatory actions affecting pharmacists’ workplace conditions
    2. Explain how a refusal to fill a legitimate prescription might result in civil liability
    3. Identify emerging approaches to containing the cost of drugs

    Release and Expiration Dates

    Released:  December 16, 2022
    Expires:  December 16, 2025

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-22-054-H03-P

    Session Code

    22RW54-ABC28

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-054-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Jennifer A. Osowiecki, RPh, JD
    Cox & Osowiecki, LLC
    Suffield, Connecticut  

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Attorney Osowiecki has no relationships with ineligible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test (for viewing only)

    Post Test

    Legal Perspectives on New and Evolving Issues in Pharmacy
    Post-test
    At the conclusion of this CPE activity, participants should be able to:
    1. Describe recent industry trends and regulatory actions affecting pharmacists’ workplace conditions
    2. Explain how a refusal to fill a legitimate prescription might result in civil liability
    3. Identify emerging approaches to containing the cost of drugs

    1. When thinking about health-system pharmacists who participated in a survey of well-being, which of the following is TRUE?
    A. The majority of pharmacists indicated that their organizations offered resources to improve well-being and that they had used the resources.
    B. Pharmacists who had a greater number of non-clinical duties were least likely to report negative effects on well-being.
    C. Only a small percentage of these pharmacists—14.5%—were aware of resources offered by their organizations that could help improve well-being.

    2. When reading stories published in various newspapers across the country, which of the following may be a limitation in their findings?
    A. The people who conducted the “research” are not pharmacists.
    B. The “data” is not collected in a structured, evidence-based way.
    C. The newspapers rarely fact-check information before publishing.

    3. A patient presents a prescription for emergency contraception on a Saturday evening. The sole pharmacist on duty refuses to fill it based on his religious beliefs and says he will also be the only pharmacist on duty on Sunday and Monday. Which of the following actions may INCREASE the likelihood of civil litigation?
    A. The pharmacist tells the patient nothing other than he belongs to a religious sect that considers emergency contraception an abortifacient and he will not fill it.
    B. The pharmacist tells the patient that the chain pharmacy across the street is open for another two hours, stocks the medication, and can fill the prescription.
    C. The pharmacist asks the patient if she would like him to call his coworker and ask the coworker to come in within 24 hours to fill this prescription.

    4. Which of the following prescriptions (which pharmacists refused to fill to treat COVID) resulted in a lawsuit against Walmart and Hy-vee pharmacies that was ultimately dismissed?
    A. ivermectin and hydroxychloroquine
    B. sodium hyochlorite and ivermectin
    C. hydroxychloroquine and molnupiravir

    5. Which of the following would reduce prescription drug costs for Medicare patients?
    A. The 340B Program
    B. Price disrupters and PBMs
    C. Inflation Reduction Act of 2022

    6. Which of the following terms and descriptions are matched correctly?
    A. Clear Bagging: Having the health system’s specialty pharmacy fill the prescription and transport it directly to the place where it will be given.
    B. Brown Bagging: Having a specialty pharmacy ship a medication directly to the hospital or clinic so it can be administered to the patient there.
    C. Gold Bagging: Having a patient fill a prescription by whatever means available and bring it to the hospital or doctor’s office for administration.

    Handouts

    VIDEO

    What in the World: A Global Look at Healthcare and Drugs-RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    1.       Describe the key components of global healthcare systems
    2.       Discuss the performance indicators of global health systems
    3.       Compare pharmaceutical drug spending levels and trends globally
    4.       Define medical tourism and analyze its associated risks and benefits

    Release and Expiration Dates

    Released:  December 16, 2022
    Expires:  December 16, 2025

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-22-055-H04-P

    Session Code

    22RW55-CBA96

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-055-H04-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Bisni Narayanan, PharmD
    Outpatient Pharmacy Services
    Yale New Haven Health System
    Pharmacy Supervisor- Operations
    Hamden, CT

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. Narayanan has no relationships with ineligible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test

    World Health Post Test – CE Finale

    After completing this continuing education activity, pharmacists will be able to
    1. Describe the key components of global healthcare systems
    2. Discuss the performance indicators of global health systems
    3. Compare pharmaceutical drug spending levels and trends globally
    4. Define medical tourism and analyze its associated risks and benefits

    Which of the following are key components in global health systems?

    a. Wait times, patient satisfaction, propensity to result in personal bankruptcy, number of healthcare professionals employed, accreditation

    b. Type of ownership (public vs. private), patient’s financial obligations, extent of coverage (e.g., preventive, inpatient, outpatient care, etc.)

    c. Antibiotic resistance, risk of exposure to blood borne diseases, long distance travel, exposure to unusual infections

    What is a common problem encountered in the universal payer model that is frequently used as a performance measure?

    a. High out of pocket cost of care

    b. Long wait times

    c. Higher mortality rates

    In comparison to other high-income countries, where does the U.S system’s administrative efficiency rank?

    a. 9th

    b. 10th

    c. 11th

    A student under your supervision is filling a prescription for a newly approved drug. She asks if it is a biologic and you say no, it is a drug (also called a small molecule) and explain the difference between a drug and a biologic, most of which are specialty medications. She says that she heard that long patent lives on innovative drugs fuel pharmaceutical drug spending. What do you tell her?

    a. “You are incorrect. The largest contributor to increased spending for pharmaceuticals is specialty medications”

    b. “You are incorrect. The largest contributor to increased spending for pharmaceuticals is COVID-19 therapeutics.”

    c. “You are incorrect. The largest contributor to increased spending for pharmaceuticals is over the counter medications.”

    Handouts

    VIDEO

    First-Line Medication Therapy for Type 2 Diabetes: Time for a Change? -RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    1.      List the American Diabetes Association’s recommended approach to preventing diabetes-related long-term complications.
    2.      Identify efficacy and safety data for the newest FDA-approved diabetes medication.
    3.      Recall the most recent ADA’s guideline recommendations on medication management of hyperglycemia in type 2 diabetes.

    Release and Expiration Dates

    Released:  December 16, 2022
    Expires:  December 16, 2025

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-22-058-H01-P

    Session Code

    22RW58-VXK92

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-058-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Khanh Dang, PharmD, CDCES, FNAP
    Associate Clinical Professor
    UConn School of Pharmacy
    Storrs, CT

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. Dang has no relationships with ineligible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test

    Post Test

    First-Line Therapy for Type 2 Diabetes: Time for a Change?

    1. What is the MOST IMPORTANT therapeutic goal in the management of diabetes?
    a. Reduce the A1c to <7%
    b. Prevent the development of long-term complications of diabetes
    c. Save money from costly treatments

    2. What is the most common cause of mortality in people with uncontrolled type 2 diabetes?
    a. Complications of atherosclerotic cardiovascular disease
    b. Neuropathic pain
    c. Diabetic eye disease

    3. Tirzepatide belongs to which of the following drug class?
    a. GLP-1 receptor agonists
    b. Dual GIP/GLP-1 receptor agonist
    c. SGLT2 inhibitors

    4. Mr. N, the hypothetical patient from the presentation, is prescribed tirzepatide by his PCP. Which of the following would be expected as a COMMON side effect of tirzepatide?
    a. Pancreatitis
    b. Neuropathic pain
    c. Nausea

    5. Which of the following statements is TRUE according to the 2023 American Diabetes Association’s diabetes guidelines?
    a. Four areas are equally emphasized: glycemic management, weight management, cardiovascular risk factor management, and cardiorenal protection.
    b. Glycemic control is the most important therapeutic goal and prescribers should encourage all patient to strive for a HbA1c lower than 6.
    c. Prevention of kidney complications of diabetes should be emphasized above other management strategies.

    6. Which of the following drug class is associated with the LOWEST potential for weight loss (hint: see the tables at the end of the presentation)?
    a. Biguanide (metformin)
    b. SGLT2 inhibitors
    c. GLP-1 receptor agonists

    Handouts

    VIDEO

    Immunization: Is Winter Here? – An Update on Monkey Pox and Covid Vaccines-RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    1. Discuss trends in the epidemiology of the COVID-19 pandemic and Monkeypox outbreak.
    2. Discuss current clinical data on the safety and effectiveness of (i) the bivalent COVID-19 booster vaccines and (ii) the JYNNEOS or ACAM2000 vaccines for Monkeypox.
    3. Explain whether a person would be eligible for receipt of (i) the bivalent COVID-19 booster vaccines and/or (ii) the JYNNEOS or ACAM2000 vaccines for Monkeypox.

    Release and Expiration Dates

    Released:  December 16, 2022
    Expires:  December 16, 2025

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-22-059-H06-P

    Session Code

    22RW59-KXV39

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-22-059-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Jeffery Aeschlimann, PharmD
    Associate Clinical Professor-Infectious Disease Specialty
    University of Connecticut School of Pharmacy
    Storrs, CT  

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. Aeschlimann has no relationships with ineligible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test

     

    1. Good news! News reporters and Internet sites began announcing in the spring and summer of 2022 that the global pandemic had ended.  What do you think of that?
      1. YAY! Science prevailed and we obliterated that bad boy and sent it away!
      2. FAKE NEWS. Approximately 2,000 Americans still die each week from (or with) active COVID-19 disease.
      3. CORRECT, but COVID is still a major concern in our socially inclined young adults.

     

    1. What does the data say about adverse effects associated with the bivalent COVID-19 boosters?
      1. The most common adverse effects are systemic (fever, chills, fatigue)
      2. The most common adverse effects are central (headache, mental fogginess)
      3. The most common adverse effects are local (pain, erythema, swelling)

     

    1. Based on current vaccination statistics about populations that have the poorest booster coverage for COVID-19, which of the following population should pharmacists be encouraging to GET VACCINATED!?!
      1. Children age 5 or younger in the Great Lakes regions
      2. People older than 65 in the Pacific northwest
      3. Everybody everywhere
      4. Monkeypox is the name and name-changing is the game. What has the World Health organization decided to call this infection and why?
      5. It will be monk's disease, which will remove some of the stigmatizing language and remind people to live like a monk until the lesions disappear.
      6. It will be mpox, which is intended to dissuade people from using racist and stigmatizing language to describe people infected with this virus.
      7. It will be var-vac-human, reflecting its similarity to variola (smallpox) and vaccinia (viral vaccine for smallpox) and its zoonotic transmission.

     

     

    1. What is eczema vaccinatum?
    2. A complication of the ACAM2000 vaccination that can occur in patients who have eczema/atopic dermatitis, in which vaccinia virus disseminates to cause an extensive rash and systemic illness.
    3. A complication of the JYNNEOS vaccination that can occur in patients who have eczema/atopic dermatitis, in which vaccinia virus disseminates to cause an extensive rash and systemic illness.
    4. A complication of the ACAM2000 vaccination that can occur in patients who have any chronic skin condition, in which vaccinia virus disseminates to cause an extensive rash and systemic illness.

     

     

    1. Andi is a person living with HIV infection who also is prone to keloids. This patient wants the JYNNEOS vaccination for mpox. What is the best course of action?
      1. Administer the vaccine intradermally
      2. Administer the vaccine subcutaneously
      3. Recommend using ACAM2000 instead

     

     

    Handouts

    VIDEO